Manal Elshaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manal Elshaikh has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ismail
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha 42, Qatar
2 shared publications - Gheyath Nasrallah
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
2 shared publications - Hadi Mohamad Yassine
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
2 shared publications - Ibrahim Al Shaar
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha 42, Qatar
2 shared publications - Ibrahim Wissam Karimeh
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha 42, Qatar
2 shared publications - Israa M. Salameh
Biomedical Research Center, Qatar University, Doha 2713, Qatar
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (6) , 1302
Strengthening STD Screening Programs: Comprehensive Evaluation of High-Throughput Immunoassays for HIV and Syphilis Detection
Fourth-generation immunoassays are widely used for HIV and syphilis screening; however, false-reactive results may increase confirmatory testing and operational burden in high-throughput laboratories. This study evaluated the comparative performance of automated chemiluminescent immunoassays (MAGLUMI® HIV Ab/Ag Combi (Snibe Diagnostics Co. Ltd., Shenzhen, China), VITROS® ECiQ HIV Combo (Ortho Clinical Diagnostics, Raritan, NJ, USA), MAGLUMI® Syphilis (Snibe Diagnostics Co. Ltd., Shenzhen, China), and ARCHITECT® Syphilis TP (Abbott Diagnostics, Abbott Park, IL, USA) within a routine diagnostic algorithm, incorporating antibody differentiation immunoassays (INNO-LIA® HIV I/II Score (Fujirebio Europe N.V., Ghent, Belgium) and HIV-1 RNA PCR where applicable. A total of 240 archived serum samples for HIV testing and 180 for syphilis testing were analyzed. Agreement-based performance measures including sensitivity, specificity, overall percent agreement (OPA), and Cohen’s kappa (κ) were calculated as comparator-based estimates reflecting concordance within the routine diagnostic algorithm rather than absolute diagnostic accuracy against a universal reference standard. For comparisons with HIV-1 RNA PCR, positive and negative concordance rates are reported to reflect agreement between assays detecting different biological targets. Among samples with definitive (positive or negative) results, the MAGLUMI® HIV Ab/Ag Combi assay showed complete agreement with INNO-LIA® HIV I/II Score (κ = 1.00) and high agreement with PCR within the ARCHITECT® HIV Ag/Ab Combo-reactive subset (κ = 0.90). The VITROS® ECiQ HIV Combo assay demonstrated high agreement with INNO-LIA® HIV I/II Score (κ = 0.916) and substantial agreement with PCR (κ = 0.715), with a lower negative concordance rate with PCR observed in the ARCHITECT-reactive subset. A parallel five-modality analysis of 11 discordant samples applying the CDC 2014 algorithm demonstrated that all three immunoassay platforms successfully detected confirmed HIV-seropositive individuals with controlled viremia despite negative PCR, while MAGLUMI® HIV Ab/Ag Combi produced fewer false-reactive results than both ARCHITECT® and VITROS® in this discordant subset. Additionally, two cases showed INNO-LIA® indeterminate results with positive PCR, consistent with acute HIV infection during the early seroconversion stage; all three immunoassay platforms produced signals above the non-reactive threshold in both cases. For syphilis testing, both MAGLUMI® Syphilis and ARCHITECT® Syphilis TP assays showed complete agreement with INNO-LIA® Syphilis Score among samples with definitive results (κ = 1.00). In contrast, the RPR assay showed reduced positive predictive value (49.4%) and moderate agreement with INNO-LIA® Syphilis Score (κ = 0.52). Automated chemiluminescent immunoassay (CLIA) platforms demonstrated high agreement within a structured diagnostic algorithm in a high-throughput screening setting. Differences in assay performance were observed across platforms, particularly with respect to discordant results in the ARCHITECT-reactive PCR-evaluated subset for HIV and non-treponemal concordance for syphilis. These platforms may support more efficient laboratory workflows; however, findings should be interpreted within the context of comparator-based classification rather than absolute diagnostic accuracy.
- 9 June 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (6) , 1302
Open AccessStrengthening STD Screening Programs: Comprehensive Evaluation of High-Throughput Immunoassays for HIV and Syphilis Detection
Fourth-generation immunoassays are widely used for HIV and syphilis screening; however, false-reactive results may increase confirmatory testing and operational burden in high-throughput laboratories. This study evaluated the comparative performance of automated chemiluminescent immunoassays (MAGLUMI® HIV Ab/Ag Combi (Snibe Diagnostics Co. Ltd., Shenzhen, China), VITROS® ECiQ HIV Combo (Ortho Clinical Diagnostics, Raritan, NJ, USA), MAGLUMI® Syphilis (Snibe Diagnostics Co. Ltd., Shenzhen, China), and ARCHITECT® Syphilis TP (Abbott Diagnostics, Abbott Park, IL, USA) within a routine diagnostic algorithm, incorporating antibody differentiation immunoassays (INNO-LIA® HIV I/II Score (Fujirebio Europe N.V., Ghent, Belgium) and HIV-1 RNA PCR where applicable. A total of 240 archived serum samples for HIV testing and 180 for syphilis testing were analyzed. Agreement-based performance measures including sensitivity, specificity, overall percent agreement (OPA), and Cohen’s kappa (κ) were calculated as comparator-based estimates reflecting concordance within the routine diagnostic algorithm rather than absolute diagnostic accuracy against a universal reference standard. For comparisons with HIV-1 RNA PCR, positive and negative concordance rates are reported to reflect agreement between assays detecting different biological targets. Among samples with definitive (positive or negative) results, the MAGLUMI® HIV Ab/Ag Combi assay showed complete agreement with INNO-LIA® HIV I/II Score (κ = 1.00) and high agreement with PCR within the ARCHITECT® HIV Ag/Ab Combo-reactive subset (κ = 0.90). The VITROS® ECiQ HIV Combo assay demonstrated high agreement with INNO-LIA® HIV I/II Score (κ = 0.916) and substantial agreement with PCR (κ = 0.715), with a lower negative concordance rate with PCR observed in the ARCHITECT-reactive subset. A parallel five-modality analysis of 11 discordant samples applying the CDC 2014 algorithm demonstrated that all three immunoassay platforms successfully detected confirmed HIV-seropositive individuals with controlled viremia despite negative PCR, while MAGLUMI® HIV Ab/Ag Combi produced fewer false-reactive results than both ARCHITECT® and VITROS® in this discordant subset. Additionally, two cases showed INNO-LIA® indeterminate results with positive PCR, consistent with acute HIV infection during the early seroconversion stage; all three immunoassay platforms produced signals above the non-reactive threshold in both cases. For syphilis testing, both MAGLUMI® Syphilis and ARCHITECT® Syphilis TP assays showed complete agreement with INNO-LIA® Syphilis Score among samples with definitive results (κ = 1.00). In contrast, the RPR assay showed reduced positive predictive value (49.4%) and moderate agreement with INNO-LIA® Syphilis Score (κ = 0.52). Automated chemiluminescent immunoassay (CLIA) platforms demonstrated high agreement within a structured diagnostic algorithm in a high-throughput screening setting. Differences in assay performance were observed across platforms, particularly with respect to discordant results in the ARCHITECT-reactive PCR-evaluated subset for HIV and non-treponemal concordance for syphilis. These platforms may support more efficient laboratory workflows; however, findings should be interpreted within the context of comparator-based classification rather than absolute diagnostic accuracy.
- Open Access
- 19 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 693
Advancing HIV Diagnostics: Comparative Evaluation of Multisure HIV-1/2 Rapid Confirmatory Test Against Geenius and Traditional Reference Assays Within a CDC-Aligned Diagnostic Framework
Human immunodeficiency virus (HIV) remains a major global health challenge, requiring accurate diagnostic testing for early detection. Chemiluminescent immunoassay screening, particularly the Architect HIV Ag/Ab Combo assay, followed by immunoblot confirmation using INNO-LIA™ has traditionally been used in many diagnostic workflows. To address these limitations, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of an HIV-1/2 antibody differentiation immunoassay, such as the Geenius HIV-1/2 Supplemental Assay, as part of the confirmatory testing algorithm. This study evaluates the performance of two rapid HIV-1/2 confirmatory assays—the Multisure HIV-1/2 Confirmatory Test and the Bio-Rad Geenius HIV-1/2 Supplemental Assay—within a CDC-aligned diagnostic framework, with the aim of assessing Multisure as a potential alternative differentiation assay. A total of 224 archived serum samples were analyzed, including true positives (n = 38), true negatives (n = 139), false positives (n = 20), and INNO-LIA™ indeterminate samples (n = 27), as defined by Architect HIV and INNO-LIA™ results. Samples were initially screened using the Architect HIV Ag/Ab Combo assay, confirmed by INNO-LIA™ and PCR, and subsequently re-tested using Multisure HIV-1/2 and Geenius HIV-1/2 assays. Diagnostic performance metrics were evaluated. Both rapid assays demonstrated 100% sensitivity and specificity when compared with INNO-LIA™. Among INNO-LIA™ indeterminate samples, Multisure HIV-1/2 classified 81.5% as negative compared with 55.6% using Geenius HIV-1/2. When compared with PCR, Multisure demonstrated higher specificity (89.2%) and positive predictive value (89.5%) than Geenius (82.9% and 84.6%). No confirmed HIV-2 infections were identified in the analyzed dataset, and HIV-1 subtype information was not available for the archived samples; therefore, conclusions regarding HIV-1/2 differentiation are based primarily on assay design and antigenic targets. Multisure HIV-1/2 demonstrated strong diagnostic performance comparable to established differentiation assays and may represent a practical alternative rapid confirmatory option within CDC-aligned HIV diagnostic workflows. Further studies including larger datasets and confirmed HIV-2 infections are warranted to further validate its clinical utility.
- 19 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 693
Open AccessAdvancing HIV Diagnostics: Comparative Evaluation of Multisure HIV-1/2 Rapid Confirmatory Test Against Geenius and Traditional Reference Assays Within a CDC-Aligned Diagnostic Framework
Human immunodeficiency virus (HIV) remains a major global health challenge, requiring accurate diagnostic testing for early detection. Chemiluminescent immunoassay screening, particularly the Architect HIV Ag/Ab Combo assay, followed by immunoblot confirmation using INNO-LIA™ has traditionally been used in many diagnostic workflows. To address these limitations, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of an HIV-1/2 antibody differentiation immunoassay, such as the Geenius HIV-1/2 Supplemental Assay, as part of the confirmatory testing algorithm. This study evaluates the performance of two rapid HIV-1/2 confirmatory assays—the Multisure HIV-1/2 Confirmatory Test and the Bio-Rad Geenius HIV-1/2 Supplemental Assay—within a CDC-aligned diagnostic framework, with the aim of assessing Multisure as a potential alternative differentiation assay. A total of 224 archived serum samples were analyzed, including true positives (n = 38), true negatives (n = 139), false positives (n = 20), and INNO-LIA™ indeterminate samples (n = 27), as defined by Architect HIV and INNO-LIA™ results. Samples were initially screened using the Architect HIV Ag/Ab Combo assay, confirmed by INNO-LIA™ and PCR, and subsequently re-tested using Multisure HIV-1/2 and Geenius HIV-1/2 assays. Diagnostic performance metrics were evaluated. Both rapid assays demonstrated 100% sensitivity and specificity when compared with INNO-LIA™. Among INNO-LIA™ indeterminate samples, Multisure HIV-1/2 classified 81.5% as negative compared with 55.6% using Geenius HIV-1/2. When compared with PCR, Multisure demonstrated higher specificity (89.2%) and positive predictive value (89.5%) than Geenius (82.9% and 84.6%). No confirmed HIV-2 infections were identified in the analyzed dataset, and HIV-1 subtype information was not available for the archived samples; therefore, conclusions regarding HIV-1/2 differentiation are based primarily on assay design and antigenic targets. Multisure HIV-1/2 demonstrated strong diagnostic performance comparable to established differentiation assays and may represent a practical alternative rapid confirmatory option within CDC-aligned HIV diagnostic workflows. Further studies including larger datasets and confirmed HIV-2 infections are warranted to further validate its clinical utility.